Effect of glucopyranosylidene-spiro-thiohydantoin on glycogen metabolism in liver tissues of streptozotocin-induced and obese diabetic rats

Molecular Medicine Reports

Volumn 4, Issue 3, 2011, Pages 477-481

  Docsa, Tibor ^a   Czifrák, Katalin ^b   Hüse, Csaba ^b   Somsák, László ^b   Gergely, Pál ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Glucose analogue inhibitors; Glycogen phosphorylase; Glycogen synthase; Zucker diabetic fatty rat

Indexed keywords

ANTIDIABETIC AGENT; GLUCOPYRANOSYLIDENE SPIRO THIOHYDANTOIN; GLUCOSE; GLYCOGEN; GLYCOGEN PHOSPHORYLASE; GLYCOGEN PHOSPHORYLASE ALPHA; GLYCOGEN SYNTHASE; LIVER EXTRACT; STREPTOZOCIN; THIOHYDANTOIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; GLUCOSE BLOOD LEVEL; GLYCOGEN LIVER LEVEL; GLYCOGEN METABOLISM; LIVER; LIVER METABOLISM; MALE; MORNING DOSAGE; NONHUMAN; OBESITY; PROTEIN DEPHOSPHORYLATION; RAT; STREPTOZOCIN DIABETES;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; ENZYME ACTIVATION; GLYCOGEN; GLYCOGEN PHOSPHORYLASE; GLYCOGEN SYNTHASE; INJECTIONS, INTRAVENOUS; LIVER; MALE; MONOSACCHARIDES; OBESITY; PHOSPHORYLATION; RATS; RATS, WISTAR; RATS, ZUCKER; SPIRO COMPOUNDS;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 79953782814     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.464     Document Type: Article

References (37)

1. Colberg SE: Enhancing insulin action with physical activity to prevent and control diabetes. ACSM'S Health and Fitness Journal 12: 16-22, 2008.
2. Zimmet P, Alberti KG and Shaw J: Global and societal implications of the diabetes epidemic. Nature 414: 782-787, 2001. (Pubitemid 34000780)
3. Sai Yd, Marrero IG, Gros P, Zaghouani H, Wicker LS and Sercarz EE: Slc11a1 enhances the autoimmune diabetogenic T-cell response by altering processing and presentation of pancreatic islet antigens. Diabetes 58: 156-164, 2009.
4. Henke BR and Sparks SM: Glycogen phosphorylase inhibitors. Mini Rev Med Chem 6: 845-857, 2006. (Pubitemid 44194372)
5. Roden M and Bernroider E: Hepatic glucose metabolism in humans - its role in health and disease. Best Pract Res Clin Endocrinol Metab 17: 365-383, 2003.
6. Choi K and Kim YB: Molecular mechanism of insulin resistance in obesity and type 2 diabetes. Korean J Intern Med 25: 119-129, 2010.
7. Magnusson I, Rothman DL, Gerard DP, Katz LD and Shulman GI: Contribution of hepatic glycogenolysis to glucose production in humans in response to a physiological increase in plasma glucagon concentration. Diabetes 44: 185-189, 1995.
8. Diraison F, Large V, Brunengraber H and Beylot M: Non-invasive tracing of liver intermediary metabolism in normal subjects and in moderately hyperglycaemic NIDDM subjects. Evidence against increased gluconeogenesis and hepatic fatty acid oxidation in NIDDM. Diabetologia 41: 212-220, 1998.
9. Andersen B, Rassov A, Westergaard N and Lundgren K: Inhibition of glycogenolysis in primary rat hepatocytes by 1, 4-dideoxy-1,4-imino-d- arabinitol. Biochem J 342 (Pt 3): 545-550, 1999. (Pubitemid 29452639)
10. Treadway JL, Mendys P and Hoover DJ: Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 10: 439-454, 2001. (Pubitemid 32186142)
11. Somsak L, Nagya V, Hadady Z, Docsa T and Gergely P: Glucose analog inhibitors of glycogen phosphorylases as potential antidiabetic agents: recent developments. Curr Pharm Des 9: 1177-1189, 2003. (Pubitemid 36582253)
12. Czifrak K, Kovacs L, Kover KE and Somsak L: Synthesis of some derivatives of C-(1-deoxy-1-N-substituted-D-glucopyranosyl) formic acid (D-gluco-hept-2-ulopyranosonic acid) as potential inhibitors of glycogen phosphorylase. Carbohydr Res 340: 2328-2334, 2005. (Pubitemid 41268657)
13. Somsak L, Czifrak K, Toth M, et al: New inhibitors of glycogen phosphorylase as potential antidiabetic agents. Curr Med Chem 15: 2933-2983, 2008.
14. Oikonomakos NG and Somsak L: Advances in glycogen phosphorylase inhibitor design. Curr Opin Investig Drugs 9: 379-395, 2008. (Pubitemid 351507664)
15. Agius L: Physiological control of liver glycogen metabolism: lessons from novel glycogen phosphorylase inhibitors. Mini Rev Med Chem 10: 1175-1187, 2010.
16. Gerich JE: Control of glycaemia. Baillieres Clin Endocrinol Metab 7: 551-586, 1993.
17. Gerich JE and Nurjhan N: Gluconeogenesis in type 2 diabetes. Adv Exp Med Biol 334: 253-258, 1993. (Pubitemid 23303363)
18. Tung HY, Alemany S and Cohen P: The protein phosphatases involved in cellular regulation. 2. Purification, subunit structure and properties of protein phosphatases-2A0, 2A1, and 2A2 from rabbit skeletal muscle. Eur J Biochem 148: 253-263, 1985. (Pubitemid 15093611)
19. Somsak L, Kovacs L, Toth M, et al: Synthesis of and a comparative study on the inhibition of muscle and liver glycogen phosphorylases by epimeric pairs of d-gluco- and d-xylopyranosylidene-spiro-(thio)hydantoins and N-(d-glucopyranosyl) amides. J Med Chem 44: 2843-2848, 2001. (Pubitemid 32879725)
20. Szkudelski T: The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 50: 537-546, 2001.
21. Griffen SC, Wang J and German MS: a genetic defect in beta-cell gene expression segregates independently from the fa locus in the ZDF rat. Diabetes 50: 63-68, 2001. (Pubitemid 32047982)
22. Praly JP and Vidal S: Inhibition of glycogen phosphorylase in the context of type 2 diabetes, with focus on recent inhibitors bound at the active site. Mini Rev Med Chem 10: 1102-1126, 2010.
23. Bichard CJF, Mitchell EP, Wormald MR, et al: Potent inhibition of glycogen-phosphorylase by a spirohydantoin of glucopyranose - first pyranose analogs of hydantocidin. Tetrahedron Letters 36: 2145-2148, 1995.
24. Osz E, Somsak L, Szilagyi L, et al: Efficient inhibition of muscle and liver glycogen phosphorylases by a new glucopyranosylidene-spiro-thiohydantoin. Bioorg Med Chem Lett 9: 1385-1390, 1999. (Pubitemid 29232212)
25. Somsak L, Nagy V, Docsa T, Toth B and Gergely P: Gram-scale synthesis of a glucopyranosylidene-spiro-thiohydantoin and its effect on hepatic glycogen metabolism studied in vitro and in vivo. Tetrahedron-Asymmetry 11: 405-408, 2000. (Pubitemid 30125484)
26. Somsak L and Nagy V: A new, scalable preparation of a glucopyranosylidene-spiro-thiohydantoin: one of the best inhibitors of glycogen phosphorylases. Tetrahedron Asymmetry 11: 1719-1727, 2000. (Pubitemid 30320893)
27. Farkas I, Toth B, Bot G and Gergely P: Hormonal regulation of phosphorylase phosphatase activity in rat liver. FEBS Lett 203: 253-256, 1986. (Pubitemid 16046806)
28. Dopere F, Goris J, Vandenheede Jr and Merlevede W: Cyclic AMP- and Ca2+-independent glycogen synthase kinase from dog liver. Biochem Soc Trans 8: 526-527, 1980.
29. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
30. Lo S, Russell JC and Taylor AW: Determination of glycogen in small tissue samples. J Appl Physiol 28: 234-236, 1970.
31. Stalmans W, Bollen M and Mvumbi L: Control of glycogen synthesis in health and disease. Diabetes Metab Rev 3: 127-161, 1987. (Pubitemid 17002811)
32. Bolzan AD and Bianchi MS: Genotoxicity of streptozotocin. Mutat Res 512: 121-134, 2002. (Pubitemid 35441051)
33. Oikonomakos NG, Skamnaki VT, Osz E, et al: Kinetic and crystallographic studies of glucopyranosylidene spirothiohydantoin binding to glycogen phosphorylase B. Bioorg Med Chem 10: 261-268, 2002. (Pubitemid 33121252)
34. Khandelwal RL, Zinman SM and Zebrowski EJ: The effect of streptozotocin-induced diabetes and of insulin supplementation on glycogen metabolism in rat liver. Biochem J 168: 541-548, 1977. (Pubitemid 8246943)
35. Furukawa S, Murakami K, Nishikawa M, Nakayama O and Hino M: FR258900, a novel glycogen phosphorylase inhibitor isolated from Fungus No. 138354. II. Anti-hyperglycemic effects in diabetic animal models. J Antibiot 58: 503-506, 2005.
36. Gimisis T: Synthesis of N-glucopyranosidic derivatives as potential inhibitors that bind at the catalytic site of glycogen phosphorylase. Mini Rev Med Chem 10: 1127-1138, 2010.
37. Loughlin WA: Recent advances in the allosteric inhibition of glycogen phosphorylase. Mini Rev Med Chem 10: 1139-1155, 2010.